Thursday Edition
Friday Edition
Head-to-head (to head) studies
Switching/sequencing studies
New analyses of DMT effectiveness
Use of gadolinium – consensus statement
Pregnancy rate on the increase in women with MS Read More
Neurology
ECTRIMS 2017 DAILY REPORT – FRIDAY EDITION
October 27, 2017ECTRIMS 2017 DAILY REPORT – THURSDAY EDITION
October 26, 2017Cladribine: intermittent immunosuppression in MS
September 21, 2017SPECIAL REPORT
The next disease-modifying therapy (DMT) expected to become available in Canada is cladribine, an oral agent initially developed a decade ago (see The return of cladribine in RRMS, NeuroSens, August 23, 2017). The drug was approved by the European Medicines Agency in June, and is currently in review with Health Canada.
New findings on gut microbiome and MS
September 13, 2017A number of recent studies have suggested that alterations in the gut microbiome (dysbiosis) may contribute to the onset and/or worsening of multiple sclerosis. Two new papers, scheduled for publication this week, report that certain bacterial strains promote neurodegeneration in the EAE mouse model (Cekanaviciute and colleagues. PNAS 2017; in press). Read More